Plain-English translation of NCT06891144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study—meaning researchers will follow your medical journey rather than test a new medication. If you are 60 or older with acute myeloid leukemia (a serious blood cancer) and are receiving intensive chemotherapy as your standard treatment, researchers want to track how you respond to treatment and what factors affect your outcome. By collecting information from 1,000 patients like you across France, the study aims to better understand who benefits most from intensive chemotherapy and how to improve care.
Acute myeloid leukemia is more common in older adults, yet we don't have clear information about how many older patients in France are able to receive intensive chemotherapy or how well they do with this treatment. This study will help doctors understand the real-world outcomes and identify which older patients benefit most from intensive treatment, so future care can be better tailored to individual patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you will not receive a new experimental treatment—you'll continue with the standard intensive chemotherapy your doctor has already recommended. Researchers will collect information about your medical condition, your treatment, and how you respond over time by reviewing your medical records and keeping track of your progress. This typically involves regular visits with your doctors as part of your normal cancer care, with no extra appointments needed just for the study.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France